Printer Friendly

"reMYND - Product Pipeline Review - 2015" is now available at Fast Market Research.

[ClickPress, Fri Oct 23 2015]

Global Markets Direct's, 'reMYND - Product Pipeline Review - 2015', provides an overview of the reMYND's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of reMYND's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Full Report Details at

-

http://www.fastmr.com/prod/1058508_remynd_product_pipeline_2015.aspx?afid=301

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Report Scope

* The report provides brief overview of reMYND including business description, key information and facts, and its locations and subsidiaries

* The report reviews current pipeline of reMYND's human therapeutic division and enlists all their major and minor projects

* The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

* Special feature on out-licensed and partnered product portfolio

* The report summarizes all the dormant and discontinued pipeline projects

* Latest company statement

* Latest news and deals relating to the reMYND's pipeline products

Reasons to Get this Report

* Evaluate reMYND's strategic position with total access to detailed information on its product pipeline

* Assess the growth potential of reMYND in its therapy areas of focus

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

Copyright [c] 2015 ClickPress Provided by SyndiGate Media Inc. ( Syndigate.info ).
COPYRIGHT 2015 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:ClickPress
Date:Oct 23, 2015
Words:467
Previous Article:Kaken Pharmaceutical Co., Ltd. - Product Pipeline Review - 2015 - New Study Released.
Next Article:Newly released market study: Europe Radioimmunoassay Market - Analysis & Forecast to 2020.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters